Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
16
Recruiting, any sponsor type, condition "chronic weight management"
By trial status
The same filters, counted in each status. Pick one to switch.
16 trials
Showing 1 to 16, recently updated first.
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07874633 · 432 participants (planned) · Start Oct 28, 2026 · Primary completion Jun 6, 2028
Drug: Berobenatide · For: Obesity; Overweight
Sites: Hefei, China; Beijing, China; Huizhou, China · 6 sites in all
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07792954 · 300 participants (planned) · Start Sep 24, 2026 · Primary completion Mar 14, 2028
Drug: Berobenatide · For: Obesity; Overweight
Sites: Hefei, China; Beijing, China; Chongqing, China · 34 sites in all
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06672549 · 125 participants (planned) · Start Nov 18, 2024 · Primary completion Feb 2027
Drug: Orforglipron; Placebo · For: Obesity; Overweight
Sites: Tucson, Arizona; Loma Linda, California; Los Angeles, California · 117 sites in all
Ascletis Pharma (China) Co., LimitedIndustry
NCT07893106 · 86 participants (planned) · Start Oct 13, 2026 · Primary completion Apr 2027
Drug: ASC36 tablets, for oral use; ASC36 placebo tablets · For: Chronic Weight Management
Sites: South Miami, Florida
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or OverweightPivotal-lookingRecruiting
Ascletis Pharma (China) Co., LimitedIndustry
NCT07893093 · 144 participants (planned) · Start Sep 28, 2026 · Primary completion Jun 2027
Drug: ASC36 Injection A, for subcutaneous use; ASC36 Placebo Injection A, for subcutaneous use and 2 more · For: Chronic Weight Management
Sites: San Antonio, Texas; Salt Lake City, Utah
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)Pivotal-lookingRecruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07654374 · 1,100 participants (planned) · Start Jul 17, 2026 · Primary completion Sep 2028
Drug: aleniglipron; aleniglipron and 2 more · For: Obesity; Overweight; Chronic Weight Management and 1 more
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 74 sites in all
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06143956 · 1,481 participants (planned) · Start Nov 17, 2023 · Primary completion Sep 2027
Drug: LY3305677; LY3841136 and 5 more · For: Obesity; Overweight
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 57 sites in all
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07684144 · 950 participants (planned) · Start Jul 29, 2026 · Primary completion Dec 26, 2027
Drug: Maridebart Cafraglutide; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Gilbert, Arizona; Canoga Park, California; Cerritos, California · 45 sites in all
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07684235 · 3,200 participants (planned) · Start Jul 23, 2026 · Primary completion Dec 26, 2027
Drug: Maridebart cafraglutide; Placebo · For: Obesity; Overweight
Sites: Anniston, Alabama; Daphne, Alabama; Mobile, Alabama · 92 sites in all
Ascletis Pharma (China) Co., LimitedIndustry
NCT07842640 · 84 participants (planned) · Start Aug 27, 2026 · Primary completion Jun 2027
Drug: ASC35 Injection B, for subcutaneous use; ASC35 Placebo Injection B, for subcutaneous use and 1 more · For: Chronic Weight Management
Sites: Baltimore, Maryland
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesPivotal-lookingRecruiting
Ascletis Pharma (China) Co., LimitedIndustry
NCT07743463 · 3,003 participants (planned) · Start Aug 31, 2026 · Primary completion Jul 2028
Drug: ASC30 tablets A1; Placebo · For: Obesity; Overweight; Chronic Weight Management
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 122 sites in all
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesPivotal-lookingRecruiting
Ascletis Pharma (China) Co., LimitedIndustry
NCT07743450 · 1,560 participants (planned) · Start Aug 28, 2026 · Primary completion Jul 2028
Drug: ASC30 tablets A1; Placebo · For: Obesity; Overweight; Chronic Weight Management and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Peoria, Arizona · 135 sites in all
- A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07670884 · 675 participants (planned) · Start Jul 24, 2026 · Primary completion Oct 31, 2027
Drug: HRS9531 Tablet; HRS9531 Tablet Placebo · For: Chronic Management of Body Weight
Sites: Zhengzhou, China; Nanjing, China
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)Pivotal-lookingRecruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07654361 · 3,600 participants (planned) · Start Jul 13, 2026 · Primary completion Sep 2028
Drug: Aleniglipron; Placebo · For: Obesity; Overweight; Chronic Weight Management
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City West, Arizona · 71 sites in all
Western University, CanadaAcademic, hospital or other
NCT06396416 · 60 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 30, 2026
Drug: Semaglutide · For: Obesity; Chronic Kidney Disease
Sites: London, Canada
- IVIG vs SCIG in CIDPRecruiting
Rutgers, The State University of New JerseyAcademic, hospital or other
NCT05584631 · 20 participants (planned) · Start Sep 11, 2022 · Primary completion Dec 1, 2026
Drug: Intravenous immune globulin G; Subcutaneous immune globulin G · For: CIDP; Immunoglobulin Deficiency; Chronic Inflammatory Demyelinating Polyneuropathy
Sites: New Brunswick, New Jersey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.